Jeevan Scientific Technology Ltd (JSTL) — shareholding pattern, promoter holding, financials and share price
About Jeevan Scientific Technology Ltd (JSTL)
Jeevan Scientific Technology Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as JSTL and on the BSE under scrip code 538837. Its ISIN is INE237B01018.
Incorporated in 1999, Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization which offers technology-driven clinical research solutions [1]
Jeevan Scientific Technology Ltd is an independent clinical contract research organization (CRO) focusing on delivering technology-driven clinical research solutions globally.
Initially, the company diversified into product development for various industries like edible oil and hospital management, highlighting a broad operational scope.
Listed peers in Healthcare Research, Analytics & Technology: Bilcare Ltd, Globalspace Technologies Ltd, Novelix Pharmaceuticals Ltd, Adeshwar Meditex Ltd, Vanta Bioscience Ltd, Docmode Health Technologies Ltd.
Valuation & Returns
10 Jul 2026At ₹70.7 a share on 10 Jul 2026, Jeevan Scientific Technology Ltd (JSTL) was valued at a price-to-earnings ratio of 136.73x against an industry P/E of 61.73x and a price-to-book of 2.82x on a book value of ₹25.07 per share as of Mar 2025. Solomo computes return on equity of 2.06% and return on capital employed of 5.86% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 136.73x
- Industry P/E
- 61.73x
- P/B
- 2.82x
- EPS (TTM)
- ₹0.52
- Book value / share
- ₹25.07
- ROE
- 2.06%
- ROCE
- 5.86%
- ROA
- 1.32%
- Debt / equity
- 0.41x
- Dividend yield
- 0%
- EBITDA margin
- 17.5%
- 52-week range
- ₹32.85 – ₹93.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Jeevan Scientific Technology Ltd (JSTL) reported revenue of ₹61.54 crore, net profit of ₹1.03 crore and earnings per share of ₹0.58. That compares with revenue of ₹46.84 crore and net profit of ₹0.05 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹21.29 crore and net profit ₹1.84 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 67.79 | 36.18 | 39.65 | 46.84 | 61.54 |
| Net profit (₹ cr) | 11.94 | -3.07 | -1.33 | 0.05 | 1.03 |
| EPS (₹) | 7.8 | -1.97 | -0.84 | 0.08 | 0.58 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.79% | 16.22% | -8.30% | 18.13% |
| Profit growth | 6.44% | - | -60.85% | 104.51% |
| Stock price CAGR | 9% | -5% | 7% | 74% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 30.25% of Jeevan Scientific Technology Ltd (JSTL) (unchanged from the previous quarter). Market capitalisation was ₹141 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2014.
Largest disclosed public shareholders in Jun 2026: CHENNAMANENI SUSHMITHA 7.53%, DHEERAJ KUMAR LOHIA 2.65%, SHEELA BANGAD 2.51%, RADHIKA RAMPA 2.51%, HUF 2.41%, SHRADHA BANGAD 2.01%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 30.25% | - | - | - | 69.75% |
| Mar 2026 | 30.25% | - | - | - | 69.75% |
| Dec 2025 | 38.05% | - | - | - | 61.95% |
| Sep 2025 | 38.05% | - | - | - | 61.95% |
| Jun 2025 | 38.05% | - | - | - | 61.95% |
| Mar 2025 | 38.05% | - | - | - | 61.95% |
| Dec 2024 | 37.84% | - | - | - | 62.16% |
| Sep 2024 | 38.7% | - | - | - | 61.3% |